This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
See Cramer's multi-million dollar portfolio for FREE and get his new book Get Rich Carefully! Learn More

Impax Laboratories Reports Third Quarter 2012 Results

The following table reconciles reported net income to adjusted net income.

      Three months ended       Nine months ended

(Unaudited, amounts in millions, except per share data)

September 30, September 30,
2012     2011 2012     2011
Net income $ 20.0 $ 17.2 $ 51.1 $ 43.6
Adjusted to add (deduct):
Amortization and acquisition-related costs (a) 22.1 - 36.4 -
Generic product withdrawal costs (b) 2.0 - 2.0 -
Patent litigation settlement reimbursement (c) (5.0 ) - (5.0 ) -
Gross profit earned on Zomig® Agreement - - 46.2 -
Acquisition related in process R&D - - 1.6 -
Employee severance - - 1.9 0.8
Inventory adjustment - - 3.5 -
Lower of cost or market charge - - 1.7 -
Income tax effect   (6.6 )   -   (30.4 )   (0.3 )
Adjusted net income $ 32.5   $ 17.2 $ 109.0   $ 44.1  
 
Net income adjusted per diluted share $ 0.48 $ 0.26 $ 1.60 $ 0.66
Net income per diluted share $ 0.29 $ 0.26 $ 0.75 $ 0.65
 
 

Impax Laboratories, Inc.

Non-GAAP Financial Measures
 

The following table reconciles reported net income to adjusted EBITDA.

      Three months ended       Nine months ended

(Unaudited, amounts in millions)

September 30, September 30,
2012     2011 2012     2011
Net income $ 20.0 $ 17.2 $ 51.1 $ 43.6
Adjusted to add (deduct):
Interest income (0.3 ) (0.3 ) (0.8 ) (0.9 )
Interest expense 0.1 0.1 0.6 0.1
Depreciation and other 4.3 3.5 11.9 11.9
Income taxes   9.6     8.5     27.2     20.8  
EBITDA   33.7     29.0     90.0     75.5  
 
Adjusted to add:
Amortization and acquisition-related costs (a) 22.1 - 36.4 -
Generic product withdrawal costs (b) 2.0 - 2.0 -
Patent litigation settlement reimbursement (c) (5.0 ) - (5.0 ) -
Gross profit earned on Zomig® Agreement - - 46.2 -
Acquisition related in process R&D - - 1.6 -
Employee severance - - 1.9 0.8
Inventory adjustment - - 3.5 -
Lower of cost or market charge - - 1.7 -
Share-based compensation   3.8     3.5     12.1     9.6  
Adjusted EBITDA $ 56.6   $ 32.5   $ 190.4   $ 85.9  
 
(a)     Amortization and acquisition-related costs from the January 2012 Distribution, License, Development and Supply Agreement with AstraZeneca UK Limited and the June 2012 Development, Distribution and Supply Agreement with TOLMAR, Inc.
 
(b) The Company recorded a charge of $2.0 million related to the voluntary withdrawal from the market of bupropion XL 300 mg, manufactured by Impax and marketed through our Strategic Alliance Agreement with Teva.
 
(c) The Company received $5.0 million for reimbursement of legal fees pursuant to the settlement of litigation.
 




Stock quotes in this article: IPXL 

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
DOW 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 +2.54 0.14%
NASDAQ 4,095.5160 +9.2910 0.23%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs